NEW YORK (GenomeWeb) – Plant genome engineering firm Calyxt announced today that it has priced its planned initial public offering of 7 million shares at $8 per share, for gross proceeds of $56 million.

Calyxt had previously said that it intended to float 6.06 million shares at between $15 and $18 apiece, which would have raised $90.9 million to $109.1 million.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.

A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.

Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.

In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.